CoChat

High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron

Open access
Baum, Ulrike, Poukka, Eero, Leino, Tuija, Kilpi, Terhi, Nohynek, Hanna, Palmu, Arto A. · 2022 · BMC Infectious Diseases

Published version of a preprint

Cited by 46

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Background: The elderly are highly vulnerable to severe COVID-19. Waning immunity and emergence of Omicron have caused concerns about reduced effectiveness of COVID-19 vaccines. The objective was to estimate vaccine effectiveness (VE) against severe COVID-19 among the elderly. Methods: This nationwide, register-based cohort analysis included all residents aged 70 years and over in Finland. The follow-up started on December 27, 2020, and ended on March 31, 2022. The outcomes of interest were COVID-19-related hospitalization and intensive care unit (ICU) admission timely associated with SARS-CoV-2 infection. VE was estimated as one minus the hazard ratio comparing the vaccinated and unvaccinated and taking into account time since vaccination. Omicron-specific VE was evaluated as the effectiveness observed since January 1, 2022. Results: The cohort included 896,220 individuals. Comirnaty (BioNTech/Pfizer) VE against COVID-19-related hospitalization was 93% (95% CI 89–95%) and 85% (95% CI 82–87%) 14–90 and 91–180 days after the second dose; VE increased to 95% (95% CI 94–96%) 14–60 days after the third dose. VE of other homologous and heterologous three dose series was similar. Protection against severe COVID-19 requiring ICU treatment was even better. Since January 1, 2022, Comirnaty VE was 98% (95% CI 92–99%) and 92% (95% CI 87–95%) 14–90 and 91–180 days after the second and 98% (95% CI 95–99%) 14–60 days after the third dose. Conclusions: VE against severe COVID-19 is high among the elderly. It waned slightly after two doses, but a third restored the protection. VE against severe COVID-19 remained high even after the emergence of Omicron.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12879-022-07814-4

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 17

  1. Baum U, Poukka E, Palmu AA, Salo H, Lehtonen TO, Leino T. Effectiveness of vaccination against SARS-CoV-2 infection and COVID-19 hospitalisation among Finnish elderly and chronically ill—an interim analysis of a nationwide cohort study. PLoS ONE. 2021;16(11): e0258704. · DOI
  2. THL recommends offering a third coronavirus vaccine dose to those over 60 and for medical high-risk groups—Press release—THL. Finnish Institute for Health and Welfare (THL), Finland. https://thl.fi/en/web/thlfi-en/-/thl-recommends-offering-a-third-coronavirus-vaccine-dose-to-those-over-60-and-for-medical-high-risk-groups. Accessed 16 Dec 2021.
  3. Poukka E, Baum U, Palmu AA, Lehtonen TO, Salo H, Nohynek H, et al. Cohort study of COVID-19 vaccine effectiveness among healthcare workers in Finland, December 2020–October 2021. Vaccine. 2022;40(5):701–5. · DOI · Paper page
  4. Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic COVID-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Europe. 2021;11: 100249. · DOI · Paper page
  5. Berec L, Šmíd M, Přibylová L, Májek O, Pavlík T, Jarkovský J, et al. Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. PLoS ONE. 2022;17(7): e0270801. · DOI
  6. Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina. N Engl J Med. 2022;386(10):933–41. · DOI · Paper page
  7. Machado A, Kislaya I, Rodrigues AP, Sequeira D, Lima J, Cruz C, et al. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: a cohort study based on data-linkage of national registries February–September 2021. PLoS ONE. 2022;17(9): e0274008. · DOI
  8. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, et al. Protection against COVID-19 by BNT162b2 booster across age groups. N Engl J Med. 2021;385(26):2421–30. · DOI · Paper page
  9. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022;386(16):1532–46. · doi:10.1056/nejmoa2119451 · Paper page
  10. Drawz PE, DeSilva M, Bodurtha P, Benitez GV, Murray A, Chamberlain AM, et al. Effectiveness of BNT162b2 and mRNA-1273 second doses and boosters for SARS-CoV-2 infection and SARS-CoV-2 related hospitalizations: a statewide report from the Minnesota Electronic Health Record Consortium. Clin Infect Dis. 2022 Feb 7;ciac110. · doi:10.1101/2021.12.23.21267853
  11. Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities—surveillance results from southern Sweden, July 2021 to January 2022. Eurosurveillance. 2022. https://doi.org/10.2807/1560-7917.ES.2022.27.9.2200121. · DOI
  12. Salo H, Lehtonen T, Auranen K, Baum U, Leino T. Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: a population-based register study with implications to vaccinations. Vaccine. 2022;40(24):3345–55. · DOI
  13. Baum U, Kulathinal S, Auranen K. Spotlight influenza: estimation of influenza vaccine effectiveness in elderly people with assessment of residual confounding by negative control outcomes, Finland, 2012/13 to 2019/20. Eurosurveillance. 2021. https://doi.org/10.2807/1560-7917.ES.2021.26.36.2100054. · DOI
  14. Rose A, Kissling E, Emborg HD, Larrauri A, McMenamin J, Pozo F, et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Eurosurveillance. 2020. https://doi.org/10.2807/1560-7917.ES.2020.25.10.2000153. · DOI
  15. Lytras T, Kontopidou F, Lambrou A, Tsiodras S. Comparative effectiveness and durability of COVID‐19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign. J Med Virol. 2022;jmv.27934. · DOI
  16. THL. Expert group on vaccines recommends longer gap between coronavirus vaccinations and giving AstraZeneca vaccine to those under 70—Press release—THL. Finnish Institute for Health and Welfare (THL), Finland. https://thl.fi/en/web/thlfi-en/-/expert-group-on-vaccines-recommends-longer-gap-between-coronavirus-vaccinations-and-giving-astrazeneca-vaccine-to-those-under-70. Accessed 2 Mar 2022.
  17. Amirthalingam G, Bernal JL, Andrews NJ, Whitaker H, Gower C, Stowe J, et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat Commun. 2021;12(1):7217. · doi:10.1038/s41467-021-27410-5

Cited by

See all 46

Metadata

Authors
Baum, U., Poukka, E., Leino, T., Kilpi, T., Nohynek, H., & Palmu, A. A.
Venue
BMC Infectious Diseases
Published
2022-11-05
Volume
22
Issue
1
Pages
816-816
ISSN
1471-2334 (ISSN-L)
OpenAlex
W4308496305
Cited by
46
References
18
FWCI
5.22
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. https://app.cochat.ai/papers/10.1186/s12879-022-07814-4
The paper
Baum, U., Poukka, E., Leino, T., Kilpi, T., Nohynek, H., & Palmu, A. A. (2022). High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. BMC Infectious Diseases. https://doi.org/10.1186/s12879-022-07814-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.